Thrivent Financial for Lutherans
EGRX

Thrivent Financial for Lutherans’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,319
Closed -$293K – 2555
2023
Q1 		$293K Sell
10,319
-362
-3% -$10.7K ﹤0.01% 2296
2022
Q4 		$312K Sell
10,681
-305
-3% -$9.7K ﹤0.01% 2248
2022
Q3 		$290K Buy
10,986
+7
+0.1% +$257 ﹤0.01% 2238
2022
Q2 		$488K Buy
10,979
+1,728
+19% +$79.4K ﹤0.01% 2110
2022
Q1 		$458K Buy
9,251
+3
+0% +$144 ﹤0.01% 2213
2021
Q4 		$471K Sell
9,248
-68
-0.7% -$3.52K ﹤0.01% 2209
2021
Q3 		$520K Sell
9,316
-222
-2% -$10.9K ﹤0.01% 2166
2021
Q2 		$408K Buy
9,538
+12
+0.1% +$495 ﹤0.01% 2246
2021
Q1 		$398K Sell
9,526
-73
-0.8% -$3.39K ﹤0.01% 2305
2020
Q4 		$447K Sell
9,599
-443
-4% -$20.7K ﹤0.01% 2176
2020
Q3 		$427K Buy
10,042
+1,563
+18% +$68.4K ﹤0.01% 2048
2020
Q2 		$407K Hold
8,479
– – ﹤0.01% 1993
2020
Q1 		$390K Buy
8,479
+424
+5% +$21.3K ﹤0.01% 1854
2019
Q4 		$484K Buy
8,055
+19
+0.2% +$1.13K ﹤0.01% 1906
2019
Q3 		$455K Sell
8,036
-48
-0.6% -$2.7K ﹤0.01% 1878
2019
Q2 		$450K Sell
8,084
-314
-4% -$16.4K ﹤0.01% 1882
2019
Q1 		$424K Buy
8,398
+673
+9% +$29.9K ﹤0.01% 1874
2018
Q4 		$311K Buy
7,725
+169
+2% +$8.71K ﹤0.01% 1795
2018
Q3 		$524K Buy
7,556
+1,847
+32% +$140K ﹤0.01% 1664
2018
Q2 		$432K Buy
5,709
+362
+7% +$22.8K ﹤0.01% 1754
2018
Q1 		$282K Buy
5,347
+32
+0.6% +$1.86K ﹤0.01% 1881
2017
Q4 		$284K Buy
5,315
+105
+2% +$5.84K ﹤0.01% 1908
2017
Q3 		$311K Sell
5,210
-823,610
-99% -$49.8M ﹤0.01% 1775
2017
Q2 		$65.4M Buy
828,820
+824,220
+17,918% +$67.4M 0.27% 95
2017
Q1 		$382K Buy
4,600
+400
+10% +$29.7K ﹤0.01% 1660
2016
Q4 		$333K Buy
4,200
+60
+1% +$4.36K ﹤0.01% 1675
2016
Q3 		$290K Buy
+4,140
New +$229K ﹤0.01% 1714

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thrivent Financial for Lutherans's EGRX Position: Q2 2023 in Review

Thrivent Financial for Lutherans sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 10,319 shares — an estimated $293K sold.

Thrivent Financial for Lutherans first reported a position in EGRX in Q3 2016 and held it in 27 quarters. The position peaked at $65.4M in Q2 2017. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Thrivent Financial for Lutherans reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 10,319 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $293K.
  • Thrivent Financial for Lutherans first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 27 quarters.
  • Thrivent Financial for Lutherans's Eagle Pharmaceuticals, Inc. position peaked at $65.4M in Q2 2017.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2023, filed 14 Aug 2023.